Based on the Spero Therapeutics Inc stock forecast from 1 analysts, the average analyst target price for Spero Therapeutics Inc is USD 7.00 over the next 12 months. Spero Therapeutics Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Spero Therapeutics Inc is Slightly Bullish , which is based on 8 positive signals and 5 negative signals. At the last closing, Spero Therapeutics Inc’s stock price was USD 1.18. Spero Therapeutics Inc’s stock price has changed by -10.61% over the past week, -4.84% over the past month and +1.72% over the last year.
No recent analyst target price found for Spero Therapeutics Inc
No recent average analyst rating found for Spero Therapeutics Inc
Company Overview Spero Therapeutics Inc
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; and Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. Spero Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts. Read Less
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebi...Read More
Frequently Asked Questions About Spero Therapeutics Inc (SPRO) Stock
Based on ratings from 1 analysts Spero Therapeutics Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bullish . The stock has 2 buy, sell and hold ratings.
Unfortunately we do not have enough data on SPRO's stock to indicate if its a good dividend stock.
Based on targets from 1 analysts, the average taret price for SPRO is USD 7.00 over the next 12 months. The maximum analyst target price is USD 7 while the minimum anlayst target price is USD 7.
SPRO stock's Price/Earning ratio is 3.47.
Our analysis grades SPRO stock's Price / Earning ratio at F. This means that SPRO stock's Price/Earning ratio is above 43.99999999999999% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this SPRO may be fairly valued for its sector
The last closing price of SPRO's stock was USD 1.18.
The most recent market capitalization for SPRO is USD 0.06B.
Based on targets from 1 analysts, the average taret price for SPRO is projected at USD 7.00 over the next 12 months.
This means that SPRO's stock price may go up by +493.22% over the next 12 months.
We can't find any ETFs which contains Spero Therapeutics Inc's stock.
As per our most recent records Spero Therapeutics Inc has 46 Employees.
Spero Therapeutics Inc's registered address is 675 Massachusetts Avenue, Cambridge, MA, United States, 02139.
You can get more information about it from Spero Therapeutics Inc's website at https://sperotherapeutics.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Underpriced compared to book value
The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior capital utilization
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior Revenue Growth
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
Superior Earnings Growth
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Spero Therapeutics Inc (SPRO) Stock
Based on ratings from 1 analysts Spero Therapeutics Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bullish . The stock has 2 buy, sell and hold ratings.
Unfortunately we do not have enough data on SPRO's stock to indicate if its a good dividend stock.
Based on targets from 1 analysts, the average taret price for SPRO is USD 7.00 over the next 12 months. The maximum analyst target price is USD 7 while the minimum anlayst target price is USD 7.
SPRO stock's Price/Earning ratio is 3.47.
Our analysis grades SPRO stock's Price / Earning ratio at F. This means that SPRO stock's Price/Earning ratio is above 43.99999999999999% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this SPRO may be fairly valued for its sector
The last closing price of SPRO's stock was USD 1.18.
The most recent market capitalization for SPRO is USD 0.06B.
Based on targets from 1 analysts, the average taret price for SPRO is projected at USD 7.00 over the next 12 months.
This means that SPRO's stock price may go up by +493.22% over the next 12 months.
We can't find any ETFs which contains Spero Therapeutics Inc's stock.
As per our most recent records Spero Therapeutics Inc has 46 Employees.
Spero Therapeutics Inc's registered address is 675 Massachusetts Avenue, Cambridge, MA, United States, 02139.
You can get more information about it from Spero Therapeutics Inc's website at https://sperotherapeutics.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for SPRO !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
